Skip to main content
Home > BC Innovations > Cover Story

Chronological Index of : Cover Story

 Current Issue
  • Figure: AKTing on SHANK3

    Rescue mission Targets & Mechanisms AKTing on SHANK3 A team at Novartis Institutes for BioMedical Research (NIBR) has identified three new autism targets (purple) and is designing small molecules against the …

    Published on 3/3/2016
  • Table: BioCentury Product Profile

    Rescue mission BioCentury Product Profile INNOVATION STAGE Product A small molecule inhibitor of CLK-2 or PPP2CA, or activator of AKT, that crosses the blood-brain barrier Concept A treatment for autism that …

    Published on 3/3/2016
  • Rescue mission

    Rescuing synapses in SHANK3 mice

    Two studies on the autism target SHANK3 suggest some symptoms can be reversed even after childhood and present a new small molecule strategy.

    Published on 3/3/2016
  • Figure: Four-armed reasoning

    Ironwood's brainy idea Product R&D Four-armed reasoning Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) wants to test its hypothesis that increased sGC signaling could mitigate Alzheimer's disease (AD) pathophysiology,…

    Published on 2/25/2016
  • Figure: NO hypertension

    Ironwood's brainy idea Product R&D NO hypertension Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) thinks the role of sGC in mediating NO-induced vasodilation can be exploited for more than just cardiovascular …

    Published on 2/25/2016
  • Table: BioCentury Product Profile

    Ironwood's brainy idea Product R&D BioCentury Product Profile BIOCENTURY PRODUCT PROFILE INNOVATION STAGE Product A soluble guanylate cyclase (sGC) stimulator that concentrates in the brain Concept A treatment…

    Published on 2/25/2016
  • Ironwood's brainy idea

    Ironwood's path to the brain

    Ironwood's preclinical group is lining up AD and vascular dementia as the next indications to explore with the company's sGC platform.

    Published on 2/25/2016
  • Figure: One fox two fox

    Staking out foxholes: Figure: One fox two fox Staking out foxholes Targets & Mechanisms One fox, two fox Researchers from Memorial Sloan Kettering Cancer Center have shown the transcription factor FOXO1 keeps Tregs …

    Published on 2/18/2016
  • Figure: Surveillance state

    Staking out foxholes: Figure: Surveillance state Staking out foxholes Targets & Mechanisms Surveillance state Researchers from Memorial Sloan Kettering Cancer Center have identified a population of immune cells that…

    Published on 2/18/2016
  • Staking out foxholes

    Two MSKCC studies, two potential ways to improve antitumor immunity

    A pair of MSKCC studies unravels new biology for dialing down immune suppression and dialing up immunosurveillance.

    Published on 2/18/2016
  • Complementary ideas

    C4 levels drive schizophrenia risk

    A link between complement and schizophrenia raises new possibilities for treatment and a debate about pruning.

    Published on 2/11/2016
  • Figure: Structured risk

    Complementary ideas Targets & Mechanisms Structured risk A Harvard group has traced one of the strongest genetic risk factors for schizophrenia to the C4 gene. The team showed structural variation in C4 controls …

    Published on 2/11/2016
  • PPP tipping point

    BioCentury's annual look shows PPPs on the backslide

    BioCentury's annual roundup suggests the trend towards public-private partnerships may have peaked.

    Published on 2/4/2016
  • Figure: Continental Differences

    PPP tipping point Finance Continental Differences While U.S.-based companies and institutions continued to put faith in public-private partnerships (PPPs) in 2015 as a vehicle for advancing research, with almost as…

    Published on 2/4/2016
  • Figure: Declining consortia

    PPP tipping point Finance Declining consortia The number of new consortium-oriented public-private partnerships (PPPs) formed in 2015 decreased from 2014, suggesting a declining trend in multilateral and complex …

    Published on 2/4/2016
  • Figure: PPP slow slide

    PPP tipping point Finance PPP slow slide The total number of public-private partnerships (PPPs) worldwide disclosed in 2015 continued a tailing off in creation of new collaborations between academia and industry …

    Published on 2/4/2016
  • Figure: Regional Tides

    PPP tipping point Finance Regional Tides California continued to play a leading role in the formation of public-private partnerships (PPPs), while the emerging biotech hub in New York led in the U.S. in terms of …

    Published on 2/4/2016
  • Figure: Top Dealers

    PPP tipping point Finance Top Dealers Leading institutes and companies in formation of public-private partnerships (PPPs) in 2015 compared with 2014. The three leading companies and two of the leading institutes …

    Published on 2/4/2016
  • Figure: Don't grow up too fast

    Peer pressure Tools & Techniques Don't grow up too fast In a Journal of Clinical Investigation study, researchers from the National Cancer Institute (NCI) showed co-culture of naïve (light blue) and memory (dark …

    Published on 1/28/2016
  • Table: BioCentury Product Profile

    Peer pressure Tools & Techniques BioCentury Product Profile BIOCENTURY PRODUCT PROFILE INNOVATION STAGE Product Naïve T cells for adoptive immunotherapy Inhibitors of FASL signaling:(a) An anti-FASL mAb(b) A …

    Published on 1/28/2016
  • Peer pressure

    Shielding naïve T cells from older cells could improve adoptive immunotherapy

    Blocking "corrupting" signals between mature and naïve T cells during in vitro culture could improve the efficacy of adoptive immunotherapy.

    Published on 1/28/2016
  • Box: Getting to the stem of DMD

    Snipping vs. skipping for DMD Targets & Mechanisms Getting to the stem of DMD Skeletal muscle stem cells - also known as satellite cells - have been largely overlooked in treatment of Duchenne muscular dystrophy (…

    Published on 1/21/2016
  • Figure: Exon skipping vs. CRISPR

    Snipping vs. skipping for DMD Targets & Mechanisms Exon skipping vs. CRISPR With the efficacy of antisense and small molecule therapeutics that bypass disease-causing mutations in Duchenne muscular dystrophy (DMD) …

    Published on 1/21/2016
  • Snipping vs. skipping for DMD

    Why CRISPR might be better than exon skipping for DMD

    Three studies show gene editing in DMD can improve muscle function in mice, but this week's setbacks for the late-stage exon-skipping compounds may have raised the bar for efficiency.

    Published on 1/21/2016
  • Moot point in AD

    A master regulator means there's no need to pick a side in β-amyloid vs. tau

    A new target upstream of β-amyloid and tau could get around the need to pick one pathway over the other.

    Published on 1/14/2016

< Previous   1  2  3  4  5  6  Next >

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993